Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx

Phathom announced that eligible commercially insured patients can pay as little as $0 for VOQUEZNA tablets exclusively through its pharmacy partner BlinkRx, with free home delivery and prior authorization support. The program applies to 30-, 60-, and 90-day fills of VOQUEZNA 10 mg or 20 mg, excludes government-insured patients and Massachusetts residents, and preserves a $55/month cash-pay option. The initiative aims to reduce abandonment and improve adherence for the company's sole marketed GERD product, though it is a patient-access program rather than a new commercial or clinical catalyst.

•6d ago

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom reported Q3 2026 net revenues of $84.7 million, up 71% year-over-year from $49.5 million and 14% sequentially, while reaffirming full-year 2026 guidance of $310-325 million in net revenue. The company generated positive operating cash flow for a second straight quarter, swung to non-GAAP adjusted net income of $3.0 million from an $11.2 million loss a year ago, and held $184.6 million in cash at quarter-end, which management says is sufficient without new debt or equity financing. Over 2 million VOQUEZNA prescriptions have been filled since launch, with ~380,000 in Q3; a new copay program via BlinkRx allows eligible commercially insured patients to pay as little as $0. Key risks and catalysts: Q4 2026 topline for the Phase 2 EoE trial, the newly initiated Phase 3 NERD as-needed study (readout expected Q1 2028), and litigation by BDR Pharmaceuticals challenging the FDA's 10-year NCE exclusivity for VOQUEZNA through May 3, 2032.

•11d ago

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

Phathom presented new predictive cost-effectiveness data at ACG 2026 projecting VOQUEZNA to be cost-effective versus PPIs in Erosive GERD, with potential healthcare savings at estimated net price. At WAC price, projected ICERs were $28,402 per QALY for the overall and $18,878 per QALY for the severe Erosive GERD population, both well below the standard $100,000 cost-effectiveness threshold. Vonoprazan was also the subject of 38 independent investigator-initiated abstracts at the meeting, which management cited as evidence of growing scientific interest in the PCAB class.

•28d ago

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Phathom Pharmaceuticals initiated patient screening in pHalcon-NERD-302, a registrational Phase 3 study of as-needed VOQUEZNA (vonoprazan) 10 mg in adults with Non-Erosive GERD, with topline results expected in Q1 2028. The trial plans to enroll approximately 500 adults across roughly 80 U.S. sites, testing whether PRN dosing provides rapid, sustained heartburn relief versus placebo, building on positive Phase 2 results. A successful readout could support a label expansion for as-needed use in NERD, a regimen not currently approved for PPIs in the U.S., potentially broadening VOQUEZNA's addressable population of an estimated 15 million U.S. NERD patients.

•1mo ago

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3 million, an 88% increase year-over-year, driven by approximately 325,000 VOQUEZNA prescriptions filled during the quarter. The company achieved operating profitability excluding stock-based compensation for the first time, with operating expenses decreasing 33% year-over-year to $63.1 million. Phathom updated its full-year 2026 revenue guidance to $310-325 million and announced the initiation of a Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA in Non-Erosive GERD patients.

•3mo ago

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom completed enrollment in its Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA for eosinophilic esophagitis (EoE), dosing 95 patients across 41 U.S. sites ahead of schedule. This trial is the first large, placebo-controlled study of an acid suppression treatment in EoE, a condition with few approved therapies where PPIs are commonly used off-label. Topline results from the 12-week treatment portion are expected in the fourth quarter of 2026, with potential for future FDA discussions regarding pediatric development.

•4mo ago

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Phathom Pharmaceuticals highlighted 31 vonoprazan-related clinical abstracts presented at Digestive Disease Week 2026, including 28 independent analyses and three sponsored studies. The company’s sponsored analysis from the Phase 3 pHalcon-NERD-301 trial received a 'Poster of Distinction' award, recognizing its scientific merit in evaluating heartburn and regurgitation in Non-Erosive GERD patients. Independent research covered a broad range of indications, including GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection care, reflecting growing scientific interest in the potassium-competitive acid blocker (PCAB) class.

•5mo ago